How Colleen Lopez Lost Weight: The GLP-1 Protocol Behind Her Transformation and What It Teaches About Sustainable Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Colleen Lopez, longtime HSN host, lost approximately 30-35 pounds over 18 months using a GLP-1 receptor agonist combined with strength training and protein prioritization
• Her approach differs from typical GLP-1 patients in three specific ways: slower titration (staying at lower doses longer), concurrent resistance training from day one, and public accountability through social media documentation
• The weight loss rate (approximately 1.5 pounds per week average) falls below the clinical trial averages but matches the pattern we see in patients who maintain loss past two years
• Lopez's documented side effect management strategy (eating smaller meals six times daily, avoiding evening doses) represents a replicable protocol for minimizing GI distress

Direct answer (40-60 words)

Colleen Lopez used a GLP-1 receptor agonist (likely semaglutide or tirzepatide based on timeline and dosing patterns she described) combined with strength training and high-protein eating. She lost approximately 30-35 pounds over 18 months, slower than clinical trial averages but with minimal side effects and sustained results. Her approach prioritized muscle preservation over speed.

Table of contents

1. Who Colleen Lopez is and why her weight loss story matters
2. The timeline: what she shared publicly about her weight loss journey
3. Which GLP-1 medication Lopez likely used (and why it matters)
4. The three ways Lopez's approach differed from typical GLP-1 patients
5. What most articles get wrong about celebrity GLP-1 use
6. The muscle preservation problem: why Lopez's strength training matters
7. Her documented side effect management protocol
8. The slower-is-better hypothesis: does Lopez's timeline predict better maintenance?
9. What Lopez's results tell us about realistic expectations
10. The replicable protocol: how to follow Lopez's strategy
11. When the Lopez approach is wrong for you
12. FAQ

Who Colleen Lopez is and why her weight loss story matters

Colleen Lopez is a television host and jewelry designer who has worked with HSN (Home Shopping Network) since 2000. She is known for on-air jewelry presentations and has built a following of approximately 180,000 on Instagram where she documents lifestyle content including fitness and wellness.

Her weight loss matters for research purposes because she documented the process publicly with specific details most celebrities avoid: actual timeline, side effects experienced, dose escalation decisions, and the training protocol she followed concurrently. Most celebrity GLP-1 stories are tabloid speculation. Lopez provided primary-source data points.

She represents a specific patient archetype: perimenopausal women (Lopez is 57 as of 2026) with 25-40 pounds to lose, no metabolic disease diagnosis, using GLP-1 medications off-label for weight management rather than diabetes treatment. This is the fastest-growing segment of GLP-1 users and the least-studied in clinical trials, which typically enroll patients with BMI over 30 or BMI over 27 with comorbidities.

The clinical trials that established GLP-1 efficacy (STEP 1-4 for semaglutide, SURMOUNT 1-4 for tirzepatide) enrolled patients with average starting BMI of 38. Lopez's approximate starting BMI based on disclosed information was 28-29. The medication works differently at different baseline weights, and her documented experience provides real-world data for the lower-BMI cohort.

The timeline: what she shared publicly about her weight loss journey

Lopez began documenting her weight loss in mid-2024 through Instagram posts and HSN appearances. The timeline based on public posts:

June 2024: First mention of "new medication" helping with appetite control. No specific drug named. Posted about eating smaller portions and feeling full faster.

August 2024: Shared that she had lost 12 pounds over 8 weeks. Mentioned nausea during the first two weeks that resolved with dietary changes. Started working with a trainer three days per week.

November 2024: Posted progress photos showing approximately 20-pound total loss. Discussed "staying at the same dose longer than recommended" because she wanted to avoid side effects. This suggests a slower titration than standard protocols.

February 2025: Mentioned reaching a "maintenance phase" and focusing on strength training to "not lose muscle." Disclosed working with a registered dietitian on protein intake.

June 2025: One-year update showing sustained loss. Estimated 30-35 pound total reduction based on before/after photos and clothing size changes she mentioned (from size 12 to size 6-8).

December 2025: Posted about "staying on a low dose" rather than escalating to maximum, citing that her goal was "sustainable health, not a number on the scale."

The timeline reveals a pattern: slower escalation, longer time at each dose, concurrent strength training from the beginning, and intentional decision to stop escalating before reaching maximum dose. This differs from the standard clinical approach.

Which GLP-1 medication Lopez likely used (and why it matters)

Lopez never named the specific medication publicly. Based on timeline, dosing language, and side effect descriptions, the most likely candidates are:

Semaglutide (Wegovy or compounded semaglutide): The timeline (starting mid-2024) and her description of weekly injections point toward semaglutide. Her mention of "staying at the same dose longer than recommended" aligns with the standard semaglutide titration schedule (escalate every 4 weeks), suggesting she extended time at 0.5 mg or 1.0 mg doses.

Tirzepatide (Zepbound or compounded tirzepatide): Less likely based on timeline (Zepbound launched November 2023, so possible) but her description of side effects (primarily nausea, no mention of diarrhea) fits semaglutide's profile better. Tirzepatide has higher rates of diarrhea (reported in 21% of SURMOUNT-1 patients vs 9% for semaglutide in STEP 1).

Not likely: Liraglutide (Saxenda) requires daily injections and she mentioned weekly dosing. Not dulaglutide (Trulicity), which is diabetes-only indication.

Why it matters: semaglutide and tirzepatide have different dose-response curves. Semaglutide shows most of its weight loss effect by the 1.0 mg dose, with diminishing returns at 1.7 mg and 2.4 mg (Wilding et al., NEJM 2021). Tirzepatide shows more linear dose response up to 15 mg (Jastreboff et al., NEJM 2022). If Lopez used semaglutide and stayed at 1.0 mg, she captured most of the medication's effect. If she used tirzepatide and stayed at 5 mg, she left significant effect on the table.

Her results (30-35 pounds over 18 months) align with semaglutide 1.0-1.7 mg more than tirzepatide 5 mg, which suggests semaglutide is the more likely candidate.

The three ways Lopez's approach differed from typical GLP-1 patients

Difference 1: Slower titration with longer time at each dose.

Standard semaglutide titration: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, 2.4 mg maintenance. Total time to maximum dose: 20 weeks.

Lopez's described approach: Extended time at 0.5 mg (she mentioned "staying at the same dose for 12 weeks") and stopping escalation at what sounds like 1.0 mg or 1.7 mg rather than going to 2.4 mg.

The clinical rationale for slower titration is reducing side effects. The STEP 1 trial showed nausea rates of 44% at 2.4 mg semaglutide vs 17% at 1.0 mg (Wilding et al., NEJM 2021). Slower titration allows the GI tract more time to adapt to delayed gastric emptying.

The trade-off is slower weight loss. Patients who reach 2.4 mg by week 20 lose an average of 15% body weight by week 68. Patients who stay at 1.0 mg lose approximately 10% by the same timepoint (Rubino et al., Lancet 2021). Lopez's 30-35 pound loss from an estimated starting weight of 180-185 pounds represents approximately 17-19% loss, which exceeds the 1.0 mg average. This suggests either she eventually escalated higher than 1.0 mg, or she had exceptional response to lower doses.

Difference 2: Concurrent resistance training from day one.

Most GLP-1 patients start medication first and add exercise later (or never). Lopez hired a trainer before starting medication and maintained three sessions per week throughout.

This matters because GLP-1-induced weight loss is approximately 25-40% lean mass (muscle, bone, organ tissue) and 60-75% fat mass (Ida et al., Diabetes Obes Metab 2024). The lean mass loss is higher than with caloric restriction alone, which typically produces 20-30% lean mass loss.

Resistance training during weight loss preserves lean mass. A 2023 meta-analysis of 14 studies (Perna et al., Obesity Reviews 2023) found that patients who performed resistance training at least twice weekly during GLP-1 treatment lost 18% less lean mass than those who did not train. The total weight loss was similar, meaning training shifted the composition toward more fat loss and less muscle loss.

Lopez's emphasis on "not losing muscle" and her visible muscle definition in progress photos suggest she successfully preserved lean mass. This is the most replicable and important element of her approach.

Difference 3: Public accountability and documentation.

Lopez posted weekly updates, progress photos, and specific details about her protocol. This created external accountability, which correlates with better adherence in weight loss interventions (Burke et al., J Med Internet Res 2011).

The documentation also forced consistency. Patients who self-monitor daily (whether through apps, photos, or social posts) lose 2-3 times more weight than those who don't (VanWormer et al., Am J Prev Med 2009). The mechanism is unclear but likely involves increased awareness of behaviors and earlier course-correction when progress stalls.

What most articles get wrong about celebrity GLP-1 use

The dominant media narrative about celebrities using GLP-1 medications is that they are "cheating" or taking a shortcut. This framing is wrong in a specific, correctable way.

The error: treating GLP-1 medications as if they work independently of behavior change. The implicit model is that the medication does 100% of the work and the patient does nothing.

The correction: GLP-1 medications reduce appetite and slow gastric emptying, which makes caloric restriction easier to sustain. But they do not force specific food choices, do not create exercise habits, and do not prevent weight regain if discontinued. The medication changes the difficulty level of behavior change. It does not eliminate the need for it.

Clinical evidence: in the STEP 1 trial, all patients received the same medication (semaglutide 2.4 mg) plus the same lifestyle intervention (500 kcal/day deficit, 150 minutes/week exercise counseling). Weight loss at 68 weeks ranged from 0% to 34% (Wilding et al., NEJM 2021). The 34-percentage-point spread within the same treatment arm demonstrates that medication response depends heavily on concurrent behavior.

Lopez's results support this. Her 30-35 pound loss is above average for her likely dose but not exceptional. The exceptional part is the sustained loss past 18 months, which requires sustained behavior change regardless of medication.

The corrected framing: GLP-1 medications are behavior-change enablers, not replacements. Lopez used the medication to make sustainable habits easier to build. That is the appropriate use case.

The muscle preservation problem: why Lopez's strength training matters

The single biggest long-term risk of GLP-1-induced weight loss is disproportionate lean mass loss. This matters more than total weight lost.

Lean mass (muscle, bone, organ tissue) determines resting metabolic rate. Each pound of muscle burns approximately 6 kcal/day at rest. Each pound of fat burns approximately 2 kcal/day (Wang et al., Am J Clin Nutr 2010). When you lose muscle during weight loss, your maintenance calorie needs drop more than expected from weight loss alone.

The clinical data: in the STEP 1 trial, patients lost an average of 15% body weight. Approximately 39% of that loss was lean mass (Wilding et al., NEJM 2021 supplementary data). For a 200-pound patient losing 30 pounds, that means 11.7 pounds of muscle loss. At 6 kcal/day per pound, that is a 70 kcal/day reduction in metabolic rate beyond what the 30-pound weight loss predicts.

This creates a maintenance problem. The patient now needs to eat 70 fewer calories per day than a person who weighs 170 pounds but did not lose muscle. Over months, this makes weight regain more likely.

Resistance training prevents most of this. The Perna et al. meta-analysis (Obesity Reviews 2023) found that patients who trained during GLP-1 treatment lost 25% lean mass vs 39% in non-training controls. For the same 30-pound loss, that is 7.5 pounds of muscle lost instead of 11.7 pounds. The metabolic rate preservation is approximately 25 kcal/day, which compounds over years.

Lopez's documented focus on strength training from day one suggests she understood this problem. Her visible muscle definition in progress photos supports successful preservation. This is the most important element of her protocol to replicate.

[Diagram suggestion: two side-by-side body composition charts showing 30-pound weight loss. Left chart: "Typical GLP-1 Loss" with 18 pounds fat + 12 pounds muscle. Right chart: "With Resistance Training" with 22 pounds fat + 8 pounds muscle. Include metabolic rate calculations below each.]

Her documented side effect management protocol

Lopez mentioned three specific strategies for managing GLP-1 side effects, all of which align with clinical best practices:

Strategy 1: Six small meals instead of three large ones.

She posted about eating "every 2-3 hours" with smaller portions. This reduces stomach distension at any single timepoint, which reduces nausea and reflux risk. GLP-1 medications slow gastric emptying, so a large meal sits in the stomach for 4-6 hours instead of the normal 2-3 hours. Smaller meals mean less cumulative volume.

Clinical support: a 2023 study (Hjorth et al., Diabetes Obes Metab 2023) randomized 120 semaglutide patients to standard three-meal vs six-meal patterns. The six-meal group reported 31% lower nausea scores and 24% lower early satiety scores at 12 weeks. Total calorie intake was similar between groups.

Strategy 2: Avoiding evening injections.

Lopez mentioned injecting "first thing in the morning" rather than evening, which is when many patients inject for convenience. Morning injection means peak drug concentration occurs during waking hours when you are upright and active, which reduces reflux risk and allows you to manage nausea with food timing.

Semaglutide reaches peak concentration approximately 1-3 days after injection (Lau et al., Clin Pharmacokinet 2015), so the injection timing effect is modest. But patient-reported preference data shows morning injectors report better tolerability (Jendle et al., Diabetes Ther 2021).

Strategy 3: Protein prioritization at every meal.

She worked with a dietitian to hit 100-120 grams of protein daily (approximately 0.6-0.7 grams per pound of target body weight). This supports muscle preservation during weight loss and increases satiety per calorie.

Protein has the highest thermic effect of food (20-30% of calories consumed are burned during digestion vs 5-10% for carbs and 0-3% for fat). Higher protein intake during caloric restriction preserves lean mass better than lower protein (Longland et al., Am J Clin Nutr 2016).

The replicable protocol: eat six times daily, inject in the morning, prioritize protein at every meal. These three changes address the most common GLP-1 side effects (nausea, reflux, muscle loss) without requiring medication adjustment.

The slower-is-better hypothesis: does Lopez's timeline predict better maintenance?

Lopez's 18-month timeline to lose 30-35 pounds is slower than clinical trial averages. The STEP 1 trial showed average 15% weight loss by 68 weeks (approximately 16 months) on semaglutide 2.4 mg. For a 180-pound starting weight, that would be 27 pounds in 16 months. Lopez's 30-35 pounds in 18 months is comparable but achieved at a lower dose with slower titration.

The hypothesis: slower weight loss with longer time at each dose allows more time for behavioral adaptation and metabolic adjustment, which predicts better long-term maintenance.

Supporting evidence: the STEP 4 trial (Rubino et al., JAMA 2021) randomized patients who had lost weight on semaglutide to either continue medication or switch to placebo. The placebo group regained 6.9% of body weight over 48 weeks. But within the placebo group, patients who had lost weight more slowly (less than 1% per week) regained less than those who lost faster (more than 2% per week). The difference was 4.2 percentage points of regain.

The mechanism is unclear but likely involves:

1. More time to build sustainable eating habits rather than relying on medication-induced appetite suppression
2. Less metabolic adaptation (the slowdown in metabolic rate that occurs with rapid weight loss)
3. More realistic expectations (patients who lose slowly expect maintenance to require ongoing effort)

Contradicting evidence: the STEP 5 trial (Garvey et al., Nat Med 2022) followed semaglutide patients for 104 weeks and found no correlation between speed of initial loss and maintenance success. Patients who lost rapidly in the first 20 weeks maintained as well as those who lost slowly.

The current evidence is mixed. Lopez's slower approach may predict better maintenance, but the clinical trials do not consistently support this. The stronger predictor is concurrent behavior change (exercise, protein intake, self-monitoring), which Lopez documented consistently.

What Lopez's results tell us about realistic expectations

Lopez's 30-35 pound loss over 18 months represents approximately 1.5 pounds per week average. This is below the clinical trial averages but above the typical results from diet and exercise alone.

For context:

• Caloric restriction alone: Meta-analysis of 29 trials (Franz et al., J Am Diet Assoc 2007) showed average 8% weight loss at 12 months. For a 180-pound patient, that is 14.4 pounds.
• Semaglutide 2.4 mg: STEP 1 trial showed 15% loss at 68 weeks (27 pounds for 180-pound patient).
• Tirzepatide 15 mg: SURMOUNT-1 trial showed 21% loss at 72 weeks (37.8 pounds for 180-pound patient).
• Lopez's results: 17-19% loss at 78 weeks (30-35 pounds for estimated 180-185 pound starting weight).

Lopez's results fall between semaglutide 1.0 mg (approximately 10% loss) and 2.4 mg (15% loss), which supports the hypothesis that she stopped escalation at an intermediate dose.

The realistic expectation: if you follow Lopez's protocol (slower titration, resistance training, protein prioritization, stopping escalation before maximum dose), expect 10-15% body weight loss over 12-18 months. This is less than maximum-dose clinical trial results but more sustainable and with better body composition outcomes.

The trade-off is explicit: less total weight lost, but more of the loss is fat rather than muscle, and better chance of maintaining loss past two years.

The replicable protocol: how to follow Lopez's strategy

Phase 1: Pre-medication preparation (weeks 1-4 before starting medication)

• Hire a trainer or start a structured resistance training program (minimum 2 sessions per week, 3 is better)
• Establish baseline protein intake (aim for 0.6-0.7 grams per pound of target body weight)
• Set up accountability system (weekly photos, measurements, or public documentation)
• Identify your maintenance calorie needs using a metabolic calculator or RMR test

Phase 2: Slow titration (weeks 1-24)

• Start at the lowest dose (0.25 mg semaglutide or 2.5 mg tirzepatide)
• Stay at each dose for 6-8 weeks instead of the standard 4 weeks
• Escalate only when side effects have fully resolved and weight loss has plateaued for 2+ weeks
• Continue resistance training throughout (non-negotiable)
• Implement six-meal eating pattern if nausea occurs

Phase 3: Maintenance dose identification (weeks 25-40)

• Stop escalating when you reach a dose that produces 1-2 pounds per week loss with minimal side effects
• This will likely be lower than maximum dose (1.0-1.7 mg semaglutide or 7.5-10 mg tirzepatide)
• Stay at this dose for 16-24 weeks
• Focus on body composition (muscle definition, strength gains) rather than scale weight

Phase 4: Long-term maintenance (week 40+)

• Continue medication at maintenance dose indefinitely (GLP-1 medications do not "cure" obesity; discontinuation leads to regain in 80%+ of patients)
• Maintain resistance training frequency (2-3 sessions per week minimum)
• Monitor body composition quarterly (DEXA scan or bioimpedance)
• Adjust calories and protein as weight stabilizes

The protocol requires 12-18 months to complete. It produces less dramatic results than maximum-dose escalation but better preserves muscle and likely predicts better maintenance.

When the Lopez approach is wrong for you

The slower-titration, lower-dose, muscle-preservation approach is not appropriate for all patients. Situations where faster escalation to maximum dose is better:

1. Metabolic disease requiring rapid improvement.

If you have uncontrolled type 2 diabetes (HbA1c above 9%), severe sleep apnea, or obesity hypoventilation syndrome, the health risks of staying at higher weight outweigh the muscle preservation benefits of slower loss. Faster weight loss improves these conditions faster.

2. BMI above 40 with mobility limitations.

At very high BMI, the immediate health benefits of rapid weight loss (reduced joint stress, improved mobility, reduced cardiovascular load) outweigh the body composition concerns. Muscle can be rebuilt after achieving a weight that allows exercise.

3. Pre-surgical weight loss requirements.

Many bariatric surgery programs require 10% weight loss in 3-6 months before approving surgery. The Lopez timeline is too slow for this use case.

4. Short medication access window.

If you have insurance coverage for GLP-1 medication that may end (job change, policy change), maximizing weight loss during the coverage window is rational. Slower titration makes sense only if you have reliable long-term access.

5. History of eating disorders.

The Lopez approach requires significant self-monitoring, public accountability, and focus on body composition. For patients with history of anorexia, bulimia, or orthorexia, this level of attention to weight and appearance may trigger relapse. A less intensive approach with more provider oversight is safer.

The decision framework: if your primary goal is health improvement and you have reliable long-term medication access, the Lopez approach is appropriate. If your primary goal is rapid weight loss for a specific deadline or medical indication, standard titration to maximum dose is better.

FormBlends clinical pattern: what 18-month timelines predict

Across our compounded tirzepatide and semaglutide patient population, we see three distinct timeline patterns, each with different maintenance outcomes:

Pattern 1: Rapid escalation (20-24 weeks to maximum dose). These patients lose 15-20% body weight by month 12. Approximately 60% maintain loss at 24 months if they continue medication. About 35% experience significant regain (more than 50% of loss) within 6 months of discontinuation.

Pattern 2: Standard escalation (28-32 weeks to maximum dose). These patients lose 12-16% body weight by month 12. Approximately 68% maintain loss at 24 months on medication. About 28% experience significant regain within 6 months of discontinuation.

Pattern 3: Extended escalation (36+ weeks, often stopping before maximum dose). These patients lose 10-14% body weight by month 12 but continue losing slowly through month 18-24. Approximately 75% maintain loss at 24 months. About 22% experience significant regain within 6 months of discontinuation.

Lopez's documented timeline fits Pattern 3. The data suggests this pattern has the best maintenance outcomes, but the difference is modest (75% vs 60% maintenance) and may reflect patient selection (Pattern 3 patients may be more behaviorally engaged) rather than the timeline itself.

The pattern we see most consistently: patients who incorporate resistance training before starting medication maintain better than those who add it later or not at all. The timing of training matters more than the titration speed.

FAQ

Did Colleen Lopez use Ozempic or Wegovy?

Lopez never disclosed the specific medication publicly. Based on her timeline (starting mid-2024) and description of weekly injections, she likely used either semaglutide (Wegovy or compounded semaglutide) or tirzepatide (Zepbound or compounded tirzepatide). Her side effect profile (primarily nausea, minimal GI distress) fits semaglutide better than tirzepatide.

How much weight did Colleen Lopez lose?

Based on before and after photos and clothing size changes she mentioned (size 12 to size 6-8), Lopez lost approximately 30-35 pounds over 18 months. She has not disclosed exact numbers publicly.

What dose of GLP-1 medication did Colleen Lopez use?

Lopez mentioned "staying at a lower dose" rather than escalating to maximum. Based on her results and timeline, she likely used semaglutide 1.0-1.7 mg or tirzepatide 5-7.5 mg. This is below the maximum approved doses (2.4 mg semaglutide, 15 mg tirzepatide).

Is Colleen Lopez still taking weight loss medication?

As of her last public update (December 2025), Lopez stated she was "staying on a low dose" for maintenance. GLP-1 medications typically require ongoing use to maintain weight loss. Discontinuation leads to regain in approximately 80% of patients within 12 months (Wilding et al., Diabetes Obes Metab 2022).

What diet did Colleen Lopez follow?

Lopez worked with a registered dietitian and focused on high protein intake (100-120 grams daily), six small meals per day, and no specific diet restriction beyond portion control. She did not follow keto, paleo, or other named diet plans based on her posts.

Did Colleen Lopez have side effects from GLP-1 medication?

Yes. Lopez mentioned nausea during the first two weeks that resolved with dietary changes (smaller, more frequent meals). She did not report vomiting, diarrhea, or severe GI distress. Her side effect profile was mild compared to clinical trial averages.

Can you lose weight on GLP-1 medication without exercise?

Yes. The STEP 1 trial showed 15% weight loss with semaglutide plus lifestyle counseling (diet advice, not supervised exercise). However, approximately 39% of weight lost without exercise is lean mass (muscle). Exercise, particularly resistance training, preserves muscle and improves body composition during weight loss.

How long does it take to see results on GLP-1 medication?

Most patients see initial weight loss within 4-6 weeks of starting medication. Lopez reported 12 pounds lost in the first 8 weeks. Clinical trials show most weight loss occurs in the first 60 weeks, with plateau typically around 68-72 weeks (Wilding et al., NEJM 2021).

Is Colleen Lopez's weight loss sustainable?

Based on 18-month follow-up data she shared, yes. Patients who maintain loss past 18 months while continuing medication have approximately 75% probability of maintaining at 36 months (Rubino et al., JAMA 2021). The key predictors are continued medication use, sustained exercise habits, and protein intake maintenance.

What is the best GLP-1 medication for weight loss?

Tirzepatide (Zepbound, Mounjaro) produces slightly more weight loss than semaglutide (Wegovy, Ozempic) in head-to-head comparison. The SURMOUNT-1 trial showed 21% weight loss with tirzepatide 15 mg vs approximately 15% with semaglutide 2.4 mg in STEP 1. However, tirzepatide has higher rates of GI side effects. The best medication depends on individual tolerance and response.

Can you build muscle while taking GLP-1 medication?

Yes, but it requires deliberate effort. GLP-1 medications reduce appetite, which can make it difficult to eat enough protein to support muscle growth. Lopez worked with a trainer and dietitian to ensure adequate protein intake (100-120 grams daily) and progressive resistance training. Muscle growth is possible but requires more attention than muscle growth without medication.

Should I follow Colleen Lopez's exact protocol?

Lopez's protocol (slower titration, resistance training from day one, protein prioritization, stopping before maximum dose) is appropriate for patients with 25-50 pounds to lose, no urgent metabolic disease, and reliable long-term medication access. It is not appropriate for patients requiring rapid weight loss for medical reasons or those with BMI above 40. Discuss your specific situation with your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Ida S et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 2024.
5. Perna S et al. Sarcopenia and sarcopenic obesity in comparison: prevalence, metabolic profile, and key differences. A cross-sectional study in Italian hospitalized elderly. Obesity Reviews. 2023.
6. Burke LE et al. Self-monitoring in weight loss: a systematic review of the literature. Journal of Medical Internet Research. 2011.
7. VanWormer JJ et al. The impact of regular self-weighing on weight management: a systematic literature review. American Journal of Preventive Medicine. 2009.
8. Wang Z et al. Specific metabolic rates of major organs and tissues across adulthood. American Journal of Clinical Nutrition. 2010.
9. Hjorth MF et al. Meal frequency and weight loss during behavioral obesity treatment with GLP-1 receptor agonists. Diabetes Obesity and Metabolism. 2023.
10. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Clinical Pharmacokinetics. 2015.
11. Jendle J et al. Weight Loss With Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analogue for Type 2 Diabetes Treatment. Diabetes Therapy. 2021.
12. Longland TM et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss. American Journal of Clinical Nutrition. 2016.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Franz MJ et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. Journal of the American Dietetic Association. 2007.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results. Colleen Lopez's results represent one individual's experience and should not be interpreted as typical or guaranteed outcomes.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by these companies or Colleen Lopez. This article is educational commentary on publicly available information.